Clinical Trial

Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The hypothesis of this proof-of-concept study is that EPO increases the frequency, stability and/or function of Tregs in liver transplant recipients. We also hypothesize that EPO will have a greater effect in everolimus vs. tacrolimus treated LTR, thus providing the rationale for a subsequent clinical trial to utilize EPO in combination with everolimus as a more successful pathway toward tolerance.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-04-05; most recent amendment 2025-09-17.
Status change: Active, Not Recruiting → Completed 2025-08-14
Status change: Recruiting → Active, Not Recruiting 2024-03-14
Trial Details
NCT Number NCT05325073
Lead Sponsor Northwestern University
Conditions Liver Transplant Rejection
Enrollment 9 participants
Start Date 2022-02-18
Primary Completion 2023-05-23 (estimated)
Study Completion 2024-09-30 (estimated)
Updated on ClinicalTrials.gov 2024-03-15